SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001824293-23-000145
Filing Date
2023-08-14
Accepted
2023-08-14 08:06:42
Documents
16
Period of Report
2023-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K val-20230814.htm   iXBRL 8-K 23505
2 EX-99.1 gri_q22023financialresults.htm EX-99.1 38374
6 GRAPHIC gri_logoselectxcolorjpga.jpg GRAPHIC 221425
7 GRAPHIC val-20230814_g1.jpg GRAPHIC 16879
8 GRAPHIC val-20230814_g2.jpg GRAPHIC 1656
  Complete submission text file 0001824293-23-000145.txt   507923

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT val-20230814.xsd EX-101.SCH 1913
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT val-20230814_lab.xml EX-101.LAB 24893
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT val-20230814_pre.xml EX-101.PRE 13067
10 EXTRACTED XBRL INSTANCE DOCUMENT val-20230814_htm.xml XML 2820
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037 (619) 400-1171
GRI BIO, Inc. (Filer) CIK: 0001824293 (see all company filings)

IRS No.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40034 | Film No.: 231166427
SIC: 2834 Pharmaceutical Preparations